Home > Neurology > ECF 2020 > ECF Round-Up Articles > No increased risk with IFN-β use during pregnancy

No increased risk with IFN-β use during pregnancy

Conference
ECF 2020
Data from the Middle East shows that exposure to subcutaneous interferon-beta (IFN-β) before and/or during pregnancy, especially in the first trimester, does not adversely affect pregnancy or infant outcomes. These findings are consistent with data collected from other registries and from the global safety database of the drug company. Women with multiple sclerosis (MS) are often diagnosed and treated at childbearing age. Therefore, family planning is an important consideration for female patients undergoing treatment. IFN-β has been recently approved for use during pregnancy and lactation. Data from different registries has shown that exposure to IFN-β before and/or during pregnancy, especially during the first trimester, did not adversely affect pregnancy or infant outcomes [1]. The objective of the presented study was to carry out a descriptive analysis of data from the safety database of the drug company in the Gulf Cooperation Council region (G...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on